

## Live webcast of the Shareholders' Meeting on Tuesday, December 15, 2020

Euronext: MEDCL • Montpellier - France • December 11, 2020 • 5:45pm CET

The Ordinary Shareholders' Meeting will be held in a closed session on Tuesday, December 15, 2020 at 5:00 p.m. CET.

A live webcast of the event will be available on the Company's website: <a href="https://invest.medincell.com/agconference/">https://invest.medincell.com/agconference/</a>
Shareholders are called to approve the appointment of Elisabeth Kogan to the Supervisory Board of MedinCell.

Access the terms and conditions for participating and voting by mail or proxy: <a href="press release of November 9">press release of November 9</a>, 2020.

## **About MedinCell**

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

## **Contacts**

MedinCell David Heuzé Communication leader <u>david.heuze@medincell.com</u> +33 (0)6 83 25 21 86

NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations medincell@newcap.eu +33 (0)1 44 71 98 53 NewCap Nicolas Merigeau Media relations medincell@newcap.eu +33 (0)1 44 71 94 98